Susceptibility of sequential Fonsecaea pedrosoi isolates from chromoblastomycosis patients to antifungal agents.
about
Melanized fungi in human diseaseBlack yeasts and their filamentous relatives: principles of pathogenesis and host defenseBeneficial effects of HIV peptidase inhibitors on Fonsecaea pedrosoi: promising compounds to arrest key fungal biological processes and virulenceIn vitro activities of eight antifungal drugs against 55 clinical isolates of Fonsecaea sppHIV Aspartic Peptidase Inhibitors Modulate Surface Molecules and Enzyme Activities Involved with Physiopathological Events in Fonsecaea pedrosoi.Subcutaneous antifungal screening of Latin American plant extracts against Sporothrix schenckii and Fonsecaea pedrosoi.Chromoblastomycosis.Photodynamic therapy combined with terbinafine against chromoblastomycosis and the effect of PDT on Fonsecaea monophora in vitro.Therapy of infections caused by dematiaceous fungi.Dematiaceous fungi.Biology and pathogenesis of Fonsecaea pedrosoi, the major etiologic agent of chromoblastomycosis.In vitro antifungal activity of naftifine hydrochloride against dermatophytesChromoblastomycosis: an overview of clinical manifestations, diagnosis and treatment.Chromoblastomycosis in Mainland China: a systematic review on clinical characteristics.Challenges in the therapy of chromoblastomycosis.In vitro evaluation of the type of interaction obtained by the combination of terbinafine and itraconazole, voriconazole, or amphotericin B against dematiaceous molds.A refractory case of chromoblastomycosis due to Fonsecaea monophora with improvement by photodynamic therapy.Antifungal therapy in an athymic murine model of chromoblastomycosis by Fonsecaea pedrosoi.In vitro susceptibility of chromoblastomycosis agents to five antifungal drugs and to the combination of terbinafine and amphotericin B.Combination of amphotericin B and terbinafine against melanized fungi associated with chromoblastomycosis.
P2860
Q24633163-CB36924A-A459-4348-87A4-050D08B35310Q27028032-65F52139-57D1-427E-9A4E-71D56685040FQ28473767-2DAE4000-E65A-41CA-AF82-1AEF5D99972DQ33525228-04282DF8-2308-4D81-ACCB-8543FDDFCAD1Q33705209-BC18671E-34AB-4761-881C-D7AE8E239584Q33904546-0C146536-B582-4069-9FDD-D8B1C7D37B67Q34457920-18091F5C-D2FE-488F-93B8-021070D5639DQ35070221-240B07F9-1B38-4F2B-89C9-C55FCE1CBAF4Q36233517-98E699CE-01C8-4442-A0BC-CBAE46E5D837Q36738130-89D82CA2-D1F6-446F-80E4-99040FEFB2ABQ36889096-D23461DA-FF47-455A-AD8B-3B86BB23F4F3Q37124023-87D0D7B4-9262-40C6-91FE-4D3061C461DAQ37351604-C24D8637-2711-4BCF-8584-2F1D17CBFC65Q38053933-6BEDEADD-7362-4B12-AECE-03C622FCD7A6Q38103473-10B18E7A-459C-427B-AD1B-91784ABBA99BQ38282878-B5D79F02-E274-4DD6-83CE-55C6FB00F06AQ39613867-B5B5E718-44A2-448E-A779-3F9DDA3A2779Q41906983-B02E8EFB-8606-4195-B420-8765E45E8565Q43571902-648AB7A3-1B9E-4422-9DA1-BEA5429215E6Q51148946-EB58E2B2-6D4F-469C-AE36-AEC29E4BCC4D
P2860
Susceptibility of sequential Fonsecaea pedrosoi isolates from chromoblastomycosis patients to antifungal agents.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh
2004年學術文章
@zh-hant
name
Susceptibility of sequential F ...... patients to antifungal agents.
@en
Susceptibility of sequential F ...... patients to antifungal agents.
@nl
type
label
Susceptibility of sequential F ...... patients to antifungal agents.
@en
Susceptibility of sequential F ...... patients to antifungal agents.
@nl
prefLabel
Susceptibility of sequential F ...... patients to antifungal agents.
@en
Susceptibility of sequential F ...... patients to antifungal agents.
@nl
P2093
P2860
P1433
P1476
Susceptibility of sequential F ...... patients to antifungal agents
@en
P2093
Arlete E Cury
Luiz G M Castro
Ricardo S Nunes
Viviane M F Gimenes
P2860
P304
P356
10.1111/J.1439-0507.2004.00984.X
P577
2004-06-01T00:00:00Z